TAKEDA PHARMA (TKD HM) stock market data APIs
€24.093
-0.16(-0.7%)
as of October 17, 2025
Try our APIs with
free plan!
TAKEDA PHARMA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for TKD.HM.
Prev. Close
24.093
Open
23.937
High
24.093
Low
23.937
52 wk Range
23.492-27.1187
Market Cap
37 823 M
Dividends (Yield)
3.2068
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TAKEDA PHARMA data using free add-ons & libraries
Get TAKEDA PHARMA Fundamental Data
TAKEDA PHARMA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TAKEDA PHARMA News
New
Keros Therapeutics to Buy Back Shares From Adar1 Capital, Pontifax for $181 Million
Keros Therapeutics (KROS) said Wednesday it has entered into share purchase agreements to buy back a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics
Nabla to receive upfront and research cost payments in double-digit millions and eligible to receive success-based payments that may exceed $1 billion Multi-year partnership deploys Nabla Bio’s AI ...
Johnson & Johnson in Talks to Buy Protagonist Therapeutics
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that would solidify the companies’ existing partnership, according to people familiar with the matter. A deal is not guarantee...
Takeda Pharmaceutical (TSE:4502): Is the Market Missing Its True Valuation Potential?
Takeda Pharmaceutical (TSE:4502) shares have been moving in line with broader market shifts, drawing attention as investors consider the company’s current valuation. While recent trading has seen mi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
